Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

A solution of (S)-(-)-alpha,alpha-diphenyl-2-pyrrolidinemethanol (240 mg, 0.97 mmol) and 2 M Borane-Dimethylsulfide complex (in THF, 3.4 mL, 6.8 mmol) in dry THF (50 mL) was stirred at rt under N2 for 16 h. A solution of 5-(4-Fluoro-phenyl)-3-oxo-pentanoic acid ethyl ester (2.03 g, 8.57 mmol) in dry THF (20 mL) was then added dropwise at rt over a period of 1 h. The resultant clear solution was stirred at rt for another 35 min and was then cooled to 0 C. in an ice bath. The reaction was quenched by the addition of EtOH (40 mL) and was concentrated under reduced pressure. The residue was taken up with EtOAc (100 mL) and washed successively with H2O (50 mL), 5% NaHCO3 (50 mL), brine (50 mL), and then dried over Na2SO4. Removal of the solvent afforded an oil, which was purified by flush column chromatography on silica gel. The intermediate S-5-(4-Fluoro-phenyl)-3-hydroxy-pentanoic acid ethyl ester was obtained as a colorless oil (1.33 g, 65%). 1H NMR (300 MHz, CDCl3) delta1.25 (t, 3H, J=7), 1.6-1.9 (m, 2H), 2.35-2.50 (m, 2H), 2.60-2.85 (m, 2H), 3.1 (d, 1H, J=5), 3.95-4.05 (m, 1H), 4.1-4.25 (m, 2H), 6.9-7.0 (m, 2H), 7.05-7.2 (m, 2H). ESMS calcd (C13H17FO3): 240.1; found: 241.1 (M+H)+.

22348-32-9, 22348-32-9 (R)-Diphenyl(pyrrolidin-2-yl)methanol 7045371, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Patent; Chen, Shoujun; Sun, Lijun; McCleary, Joel; US2003/60633; (2003); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

UO2Cl4?·(H2terpy)2?·2Cl (2): A mixture of 1.7 ml (0.2 mmol) UCl4/HCl 0.12 M, 93 mg (0.4 mmol) 2,2???:6???,2???-terpyridine and 3.3 ml (63 mmol) acetonitrile was placed in a Parr vessel and then heated statically at 120 ?°C for 48 h. The resulting yellow product was then filtered off, washed with water and dried at room temperature (reaction yield 69percent). XRD powder pattern indicated that the compound was obtained as a pure phase (Supplementary Information S3)., 1148-79-4

1148-79-4 2,2′:6′,2”-Terpyridine 70848, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Lhoste, Jerome; Henry, Natacha; Loiseau, Thierry; Guyot, Yannick; Abraham, Francis; Polyhedron; vol. 50; 1; (2013); p. 321 – 327;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937.

22348-32-9, As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

5144-89-8, 1,10-Phenanthroline hydrate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example I 2,9-bis(4methylphenyl)-1,10-phenanthroline (2). A 1.7 M solution of t-butyllithium in pentane (300 mL, 0.510 mol) was added under argon to a stirred suspension of p-iodotoluene (56.04 g, 0.257 mol) in ether (150 mL) at -78 C. The mixture was allowed to warm to room temperature over 1 h. The resulting solution of tolyllithium was added to a solution of 1,10-phenanthroline monohydrate (8.50 g, 0.043 mol) in toluene (100 mL). The resulting dark red solution was stirred under argon for 48 h. The reaction was carefully quenched with water (300 mL) and extracted with CH2 Cl2 (3*150 mL). The combined organic layers were dried (Na2 SO4) and evaporated to a volume of 500 mL under reduced pressure. The solution of crude product was oxidized by stirring with activated MnO2 (60 g). An additional portion of MnO2 (30 g) was added to the reaction after 1 h to ensure complete oxidation. After a total of 2 h, anhydrous MgSO4 (40 g) was added, and the mixture was filtered. The MnO2 /MgSO4 was washed with CH2 Cl2 (300 mL), and the solvent was concentrated to a volume of 50 mL, when a crystalline solid formed. The solution was cooled in ice and filtered. The light yellow product crystals were filtered, washed with one portion of cold toluene (20 mL), and dried. Yield 8.63 g 56%). 1 H NMR (CDCl3) delta8.38 (d, J=8.1 Hz, 4H), 8.29 (d, J=8.5 Hz, 2H), 8.13 (d, J=8.4 Hz, 2H), 7.77 (s, 2H), 7.40 (d, J=8.1 Hz, 4H), 2.47 (s, 6H)., 5144-89-8

As the paragraph descriping shows that 5144-89-8 is playing an increasingly important role.

Reference：
Patent; University of Pittsburgh of the Commonwealth System of Higher Education; US5998594; (1999); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, A solution of compound 9 (200mg, 0.39mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (212mg, 0.78mmol), and potassium hexafluorophosphate (108mg, 0.585mmol) in dry 1,2-dichloroethane (20mL) was stirred at 40°C for 24h. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 10 as a dark red solid (198mg, 50percent). 1H NMR (300MHz, CDCl3): delta 8.88 (s, 1H), 8.83 (s, 1H), 8.75 (s, 2H), 8.27 (d, J=6Hz, 1H), 8.02 (dd, J=1.5Hz, 1.5Hz, 1H), 7.80 (d, J=5.4Hz, 1H), 7.84 (d, J=6.3Hz, 1H), 7.76(dd, J=1.5Hz, 1.5Hz, 1H), 7.69 (dd, J=1.5Hz, 1.5Hz, 1H), 7.59?7.64 (m, 5H), 7.30(d, J=5.4Hz, 1H), 7.01?7.16 (m, 1H), 6.89 (q, J=5.4Hz, 1H), 6.52 (q, J=7.8Hz, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.98 (s, 3H), 3.96 (s, 3H); 13C NMR (125MHz, CDCl3): delta 181.4, 164.3, 164.3, 164.1, 163.9, 162.1, 159.5 (d, JCF=252.1Hz), 157.9, 157.3, 156.6, 156.4, 155.4, 151.6, 150.7, 150.4, 145.6, 138.4, 137.2, 136.3, 135.8, 135.7, 135.4, 135.2, 128.1, 126.2, 126.1, 125.8, 125.7, 125.1, 122.8, 122.7, 122.1, 121.9, 121.6, 120.0, 119.0, 109.5 (d, JCF=22.7Hz), 53.4, 53.3, 53.2; HRMS (FAB): calcd. for C41H31FN5O8SRu [M+] 874.0921, found 874.0923.

71071-46-0 Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate 326419, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

71071-46-0, Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

71071-46-0, General procedure: A solution of compound 5 (400mg, 0.822mmol), [(eta6-p-cymene) RuCl2]2 (252mg, 0.411mmol), and Me4NCl (450mg, 4.11mmol) in anhydrous acetone (21mL) was stirred under a dark atmosphere at room temperature for 6h. The reaction mixture was filtered and the filtrate was evaporated to afford crude compound as a bright orange solid. The above intermediate (200mg, 0.373mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (203mg, 0.746mmol), and potassium hexafluorophosphate (103mg, 0.56mmol) were dissolved in dry 1,2-dichloroethane (20mL) and the mixture was stirred at 60°C for 12h. The mixture was then concentrated under reduced pressure and the resulting crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 6 as a dark red solid (233mg, 70percent). 1H NMR (300MHz, CDCl3): delta 8.89 (s, 1H), 8.85 (s, 1H), 8.79 (s, 1H), 8.74 (s, 1H), 8.39 (d, J=5.7Hz, 1H), 8.00?7.91 (m, 3H), 7.82 (m, 3H), 7.67 (dd, J=3.6Hz, 1.5Hz, 1H), 7.52 (dt, J=8.7Hz, 1.2Hz, 1H), 7.46 (d, J=7.5Hz, 1H), 7.32?7.19 (m, 5H), 7.13 (d, J=5.7Hz, 1H), 6.72 (dt, J=6.5Hz, 1.5Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 1.27 (s, 3H); 13C NMR (125MHz, CDCl3): delta 192.8, 164.6, 164.4, 164.2, 162.6, 157.9, 157.8, 156.5, 156.3, 155.6, 151.9, 151.4, 150.5, 149.8, 142.5, 142.4, 138.4, 137.3, 136.6, 135.6, 135.3, 135.0, 134.9, 129.4, 128.5, 127.9, 127.6, 126.3, 162.2, 125.8, 123.0, 122.9, 122.4, 120.4, 118.8, 53.6, 53.5, 53.4, 53.3, 15.5; HRMS (FAB):calcd. for C44H36N5O8RuS [M+] 896.1328, found 896.1321.

As the paragraph descriping shows that 71071-46-0 is playing an increasingly important role.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.118949-61-4,2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%.

118949-61-4, As the paragraph descriping shows that 118949-61-4 is playing an increasingly important role.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1148-79-4, 2,2′:6′,2”-Terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

UO2Cl2(terpy) (3): A mixture of 1.7 ml (0.2 mmol) UCl4/HCl 0.12 M, 93 mg (0.4 mmol) 2,2???:6???,2???-terpyridine, 2.3 ml (19 mmol) acetonitrile and 1.1 ml (12 mmol) pyridine was placed in a Parr vessel and then heated statically at 120 ?°C for 48 h. The resulting yellow product was then filtered off, washed with water and dried at room temperature (reaction yield 79percent). XRD powder pattern indicated that the compound was obtained as a pure phase (Supplementary Information S3)., 1148-79-4

As the paragraph descriping shows that 1148-79-4 is playing an increasingly important role.

Reference：
Article; Lhoste, Jerome; Henry, Natacha; Loiseau, Thierry; Guyot, Yannick; Abraham, Francis; Polyhedron; vol. 50; 1; (2013); p. 321 – 327;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI